April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Long-Term Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on Intraocular Pressure
Author Affiliations & Notes
  • Quan V. Hoang
    Ophthalmology, Vitreous Retina Macula Consultants of New York, New York, New York
    LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Institute, New York, New York
  • Ron Margolis
    Ophthalmology, Vitreous Retina Macula Consultants of New York, New York, New York
    Retina Consultants, Hartford, Connecticut
  • Vivian Chin
    Ophthalmology, New York University, New York, New York
  • Angela J. Tsuang
    Ophthalmology, New York University, New York, New York
  • K. Bailey Freund
    Ophthalmology, Vitreous Retina Macula Consultants of New York, New York, New York
    Ophthalmology, New York University, New York, New York
  • Footnotes
    Commercial Relationships  Quan V. Hoang, None; Ron Margolis, None; Vivian Chin, None; Angela J. Tsuang, None; K. Bailey Freund, Alimera (C), Allergan (C), Genentech (F, C)
  • Footnotes
    Support  Financial support from the LuEsther T. Mertz Retina Research Center, Manhattan Eye, Ear, and Throat Institute, and The Macula Foundation Inc.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1690. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Quan V. Hoang, Ron Margolis, Vivian Chin, Angela J. Tsuang, K. Bailey Freund; Long-Term Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on Intraocular Pressure. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1690.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the long-term effect of intravitreal anti-vascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP).

Methods: : 133 patients without prior history of glaucoma with treatment-naïve age-related macular degeneration (AMD) treated with intravitreal anti-VEGF agents and followed for an average of 21.2 months were retrospectively reviewed for elevations in IOP (in mmHg, defined as either IOP ≥ 21, ≥ 25, or a ≥ 6 increase in IOP from baseline). The associations between number of injections and change in IOP from baseline in both treated and untreated eyes were analyzed.

Results: : A total of 149 eyes of 133 patients were included in this study. The mean patient age at the initiation of treatment was 81 years, 65% were female, and 61% of eyes were phakic. Mean pre-treatment IOP was 14.9 (standard deviation, SD 2.4, range 10-20). The mean number of total injections was 14.3 (SD 9.4, range 1-35). Overall, 8 patients (6%) experienced an elevation in IOP. Logistic regression showed a significant effect of the total number of injections on the probability of a measured IOP being ≥ 22 vs. < 22 (p = 0.010), or ≥ 25 vs. < 25 (p = 0.035), and of a ≥ 6 increase in IOP from baseline (p = 0.031). Mean number of injections received was significantly higher in those patients with an IOP ≥ 22 (26.6 injections) than those with IOP < 22 (13.7 injections, p = 0.005, two-tailed, two-sample t-test), and in those with an IOP ≥ 25 (28.3 injections) than those with IOP < 25 (13.9 injections, p = 0.008).

Conclusions: : In treatment-naïve age-related macular degeneration patients without a prior history of glaucoma, the total number of intravitreal anti-VEGF injections is a predictor of elevation in IOP.

Keywords: age-related macular degeneration • vascular endothelial growth factor • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×